Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 20/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 20/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 20/20 | 0.58 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.49 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832575 | 0.93 | CHRM2 (0.66) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trifluoroacetic Acid SCHEMBL5169877 | 0.86 | CHRM2 (0.65) | CHRM2CHRM1CHRM3 | |
| Trifluoroacetic Acid SCHEMBL5488371 | 0.85 | CHRM2 (0.71) | CHRM2CHRM1CHRM3 | |
| Trifluoroacetic Acid SCHEMBL5169868 | 0.84 | CHRM2 (0.55) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2816831 | 0.83 | CHRM2 (0.74) | CHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL5494973 | 0.82 | CHRM2 (0.74) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2831652 | 0.82 | CHRM2 (0.60) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2830411 | 0.81 | CHRM3 (0.62) | CHRM2CHRM1CHRM3 | |
| SCHEMBL2819254 | 0.81 | CHRM2 (0.73) | CHRM2CHRM1CHRM3 | |
| SCHEMBL6229872 | 0.80 | CHRM2 (0.75) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.